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 The pathophysiology of severe respiratory diseases, such as asthma and chronic 
obstructive pulmonary disease (COPD), supports the theory that oxygen deprivation to 
the brain may impact the brain’s execution of cognitive functions. Imaging studies also 
suggest that neuroanatomical changes in areas of the brain responsible for cognitive 
processes may be associated with respiratory diseases. Research in this area has failed to 
conclude definitively, especially in an older adult population, which is more likely to 
experience comorbid depression and cardiovascular disease, universally acknowledged 
predictors of poorer cognitive performance, the extent of the relationship between 
respiratory illness and cognitive functioning. The current study investigated the 
association between respiratory disease with cognitive performance in older adults, also 
considering the relative impact of cardiovascular disease and depression. Functioning 
was examined globally and in the individual domains of psychomotor functioning and 
verbal ability. Physiological measures of disease were also explored for potential 
relationships with cognition. Results suggest that depression was consistently associated 
with poorer performance across cognitive domains, whereas cardiovascular disease was 
 
primarily associated with reduced functioning in psychomotor tasks. After accounting for 
these effects, no additional association between respiratory disease and cognitive 
functioning was identified, with the possible exception of COPD relating to enhanced 
verbal ability. None of the physiological measures obtained were found to correlate with 
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The two most common respiratory diseases are asthma and chronic obstructive 
pulmonary disease (COPD). Asthma is a relatively common chronic disease that affects 
over 8% of adults in the United states (Centers for Disease Control and Prevention, 
2018). Common asthma symptoms include chest tightness, coughing or wheezing, and 
shortness of breath. A frequent physiological effect of asthma is thickening of the 
muscles comprising the airway, resulting in reduced airflow to the lungs. Certain 
conditions, such as stress, excessive activity, and infection, may subject individuals with 
asthma to hypoxemia, a low blood-oxygen level, which interferes with oxygen supply to 
vital organs, including the brain. Asthma attacks that increase the severity of asthma 
symptoms can create hypoxic conditions, resulting in potentially dangerous levels of 
oxygen deprivation. Chronic obstructive pulmonary disease (COPD), whose etiology is 
often attributed to smoking, or exposure to other pollutants, can be more severe than 
asthma, as it is chronic and progressive in nature. Diseases included under the umbrella 
of COPD are emphysema, a disease in which air is trapped in damaged parts of the lung 
preventing proper airflow, and chronic bronchitis, chronic inflammation of the channel 
that brings air to and from the lungs. Although COPD has a lower prevalence than asthma 
of just over 4% (Doney et al., 2014),  both share common symptomatology, 
pathophysiology, and the potential for functional impairment due to oxygen deprivation. 
Other respiratory diseases, such as sleep apnea, a condition that manifests in abnormal 
breathing patterns, often with pauses that delay oxygen intake, and pulmonary fibrosis, a 
condition in which scar tissue on the lung restricts oxygen flow, also result in decreased 
oxygenation. This rationale is the general basis for scientific research investigating 
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cognitive functioning in people with respiratory diseases. Cerebral oxygenation is the fuel 
for brain functions, especially motor and higher-order processes.  
 The association between respiratory disease and cognitive functioning does not 
merely stem from a theoretical argument. Neuroimaging research has demonstrated that 
patients with asthma and COPD, the two most common respiratory illnesses, can yield 
structural changes in the brain that may influence execution of cognitive abilities, 
especially in hippocampal and gray matter areas, which are particularly sensitive to 
oxygen deprivation (Caldera-Alvarado et al., 2013; Dodd et al., 2012; Esser et al., 2016; 
Moss et al., 2005). Additionally, corticosteroid use is a common form of treatment for 
both asthma and COPD, which has been implicated in cognitive impairment by way of 
affecting the hippocampus and frontal lobe (Belanoff et al., 2001; Brown et al., 1999; 
Carlson et al., 2017). These areas are particularly noteworthy as they are associated with 
executive functions, learning, memory, spatial perception, language, and emotions 
(Leupoldt et al., 2011; Lezak et al., 2004). Related structural changes in the brain 
establish an even stronger rationale for investigating neuropsychological functioning in 
this population. It should be noted, however, that some have found that while use of 
corticosteroids may have a negative impact on executive functioning and memory, it has 
been associated with a positive effect on expressive language and some other functions 
(Bozek et al., 2010; Prado & Crowe, 2019).  
 A challenge in this line of research is identifying the relative impact of comorbid 
psychological and medical conditions in the relationship between respiratory disease and 
cognitive performance. There is an abundance of literature documenting a high 
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prevalence of depression and anxiety among patients with asthma or COPD (Briraatek et 
al., 2015; Del Giacco et al., 2016; Han, Forno, Marsland, Miller, & Celedón, 2016; 
Yohannes, Willgoss, Baldwin, & Connolly, 2010) and because anxiety and depression 
are known to negatively impact neuropsychological functioning even in the absence of 
asthma or COPD (Geda et al., 2014; Rock et al., 2014), it is important to ascertain 
whether respiratory disease affects functioning in a direct path, or whether these 
psychological comorbidities account for the effect. Asthma and COPD have also been 
shown to co-occur with numerous medical comorbid diseases, most commonly 
cardiovascular and metabolic diseases and especially in elderly populations (Soriano et 
al., 2005; Su et al., 2016; Tsai et al., 2012; Wardzyńska et al., 2015; Yáñez et al., 2014). 
Similarly, cardiovascular, cerebrovascular, and metabolic diseases, such as hypertension, 
congestive heart failure, stroke, and diabetes, to name a few, have also been associated 
with cognitive impairment, further complicating the process of evaluating their relative 
impact on cognitive functioning in the presence of asthma or COPD (McCrimmon et al., 
2012; Waldstein & Elias, 2015).  
 Research to date on the relationship between respiratory disease and 
neuropsychological functioning is limited, especially with older adult populations (Irani 
et al., 2017; Tsai et al., 2012). However, numerous factors suggest that this older adult 
subset of the population deserves particular focus in the study of cognition among 
respiratory disease patients. Firstly, the above-mentioned comorbidities are more 
common in an older population, increasing the potential risk for cognitive impairment. 
Additionally, it is important to consider if and how cognitive processing among older 
patients with respiratory disease differs from normal cognitive aging among healthy older 
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adults (Irani et al., 2017). Some studies have also pointed to increased severity of 
asthma/COPD among the elderly, and an increased likelihood of consequential reduced 
cognitive functioning among older adults (Caldera-Alvarado et al., 2013; Dodd, 2015; 
Irani et al., 2017; Ray et al., 2015; Rusanen et al., 2013; Zein et al., 2015). One scientific 
approach suggests that asthma among older adults manifests in a manner phenotypically 
distinct from childhood asthma and that it is essentially classified as the same disease as 
COPD (Yáñez et al., 2014). Thus, the elderly asthma/COPD cohort becomes an important 
one to study in the context of both disease severity, as well as increased likelihood of 
psychological and medical comorbidities.  
 Research findings addressing the impact of respiratory disease (most commonly 
investigating asthma, COPD, or both) on neuropsychological functioning in the elderly 
are not only limited, but inconsistent. To summarize, some studies found minimal or no 
relationship between asthma/COPD and neuropsychological performance in the elderly 
(e.g., Caldera-Alvarado et al., 2013; Dodd, 2015; Moss et al., 2005; Salık et al., 2007), 
and others identified that asthma/COPD patients exhibited poorer cognitive performance 
than healthy counterparts (e.g., Crişan et al., 2014; Hung et al., 2009; Mourad et al., 
2017; Torres-Sánchez et al., 2015). Some of these studies used a single, brief test of 
global cognition as a proxy for neuropsychological functioning rather than several scales 
that span multiple cognitive domains. Additionally, the impact of most of these studies is 
limited due to either small sample size, lack of a comparison group to the asthma or 
COPD groups, or a failure to account for the effects of relevant comorbidities. For 
example, cardiovascular disease has long been linked with poor cognitive outcomes, 
attributed to some of the risk factors that accompany the disease, subclinical strokes, and 
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more recently, structural brain changes due to cardiovascular disease (Johansen et al., 
2020; Leritz et al., 2011). Specific deficits have been noted with higher-order functions, 
such as cognitive flexibility and processing speed, as assessed with the Digit Symbol Test 
(Hajjar et al., 2011). Others also found that cardiac health was associated with some 
higher-order cognitive processes, such as psychomotor tasks, executive functioning, and 
global cognition, but also that it was seldom associated with verbal processes. (Crichton 
et al., 2014). Additionally, psychological comorbidities like depression and anxiety have 
also been associated with poorer cognitive performance in the elderly, especially in the 
domains of processing speed, memory, attention, and executive control (Beaudreau & 
O’Hara, 2009; Geda et al., 2014; Rock et al., 2014; Shimada et al., 2014). The 
interactions of comorbidities in their relationships with each other and with cognitive 
functioning increases the complexity of investigating relative effects of each factor. 
Research evaluating the link between respiratory disease and cognitive functioning must 
properly execute sound methodological strategy as well as account for the possible 
effects of these comorbidities in order to draw translatable conclusions. 
 In a preliminary study, the current author investigated group differences in 
neuropsychological functioning between asthma, COPD, and comparison groups of older 
adults (Gordon, 2019). Using a quasi-experimental design, with a large sample size and 
numerous neuropsychological measures spanning various cognitive domains, the research 
did not reveal meaningful group differences in any of the domains assessed (executive 
functioning, complex attention, verbal memory, language, visual construction, and 
psychomotor functioning). However, despite the absence of statistically meaningful 
group differences, an observable trend suggested that COPD patients may have 
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performed more poorly than controls on tasks in which the cognitive complexity or 
psychomotor demands increased from trial to trial in the task (e.g., when using non-
dominant hand versus the dominant hand). This research, however, did not account for 
the psychological and medical comorbidities known to influence cognitive functioning 
that may have impacted the results. Additionally, unlike some of the earlier work in this 
area, physiological measures of respiratory disease function were not reviewed in the 
context of neuropsychological performance. 
 The aims of the current study were: 1) to build upon previous research on the 
impact of respiratory disease on neuropsychological functioning in older adults by 
evaluating the role of key psychological and medical comorbidities most likely to impact 
functioning (i.e., cardiovascular diseases and depression); 2) To examine the impact of a 
broad group of respiratory diseases with similar pathophysiology (e.g., including sleep 
apnea, pulmonary fibrosis) on cognition and to further explore differences between 
asthma and COPD subgroups in comparison; 3) To explore patterns of physiological 
differences between groups and their potential relationship with cognitive performance 
using measures of blood pressure and oxygen saturation levels.  In light of research 
suggesting that respiratory illness is more likely to affect more cognitively demanding 
aspects of neuropsychological functioning, especially tasks requiring cognitive flexibility 
and psychomotor functions (e.g., Irani et al., 2017; Moss et al., 2005; Rajabi, Keshavarz, 





1) It was expected that ratings for both psychological disorders (i.e., depression and 
anxiety) would correlate negatively with neuropsychological measures, indicating 
that more severe depression and anxiety would reflect poorer cognition. 
2) All neuropsychological test measures were expected to correlate with one another, 
allowing for examination of a global cognition score in addition to more specific 
domains.    
3) It was expected that both cardiovascular disease and depression would relate to 
performance on global cognition, psychomotor functioning, and verbal ability, such 
that those with self-reported cardiovascular disease and higher depression scores 
would perform more poorly in these domains than those in a reference group. 
Literature supports a hypothesis that cardiovascular disease would have the greatest 
impact in the domain of psychomotor functioning.  
4) It was also expected that after accounting for the effects of cardiovascular disease and 
depression, that respiratory disease would be related to poorer performance in all 
three domains. It was further anticipated that COPD would be more strongly 
implicated over asthma in poorer performance due to COPD’s more severe 
symptomatology.  
5) Lower oxygen and higher blood pressure levels were expected to correlate with 





The data for this study was collected from participants of the Memory Education 
and Research Initiative (MERI), an ongoing clinical research program that measures a 
wide range of medical, behavioral, cognitive, and demographic data (Reichert et al., 
2015). Participants are typically referred to the MERI for neuropsychological testing 
secondary to subjective memory complaints or concerns regarding a family history of 
dementia. Many, if not most of the MERI participants, however, are found not to be 
cognitively impaired from a clinical standpoint and comprise most of the research 
subjects included in this study. More detailed information regarding the participant pool 
has been previously published in a book chapter describing the MERI model (Reichert et 
al., 2015). Participants under the age of 60 years were excluded from this study consistent 
with previous studies of older adult cohorts using similar age cutoffs. In preliminary 
research (Gordon, 2019), subjects considered to be cognitively impaired as determined by 
Mini Mental State Examination (MMSE; Folstein, Folstein, & McHugh, 1975) scores 
below 24, a conventional cutoff for this measure (Lezak et al., 2004), were excluded. The 
current research aimed to enhance methodology by removing the MMSE cutoff criterion, 
recognizing that physical disease may facilitate cognitive impairment and by excluding 
those with clinical impairment, the overall data may have been misrepresented.  
Participants 
After excluding participants below 60 years old and who did not complete any 
neuropsychological test, a total of 969 participants were included, comprising groups of 
those without cardiovascular or respiratory disease, those with both disease types, those 
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with only cardiovascular disease, the largest subgroup, and those with only respiratory 
disease. See Figure 2 for a visual representation of these groups. Participants had mean 
age of 74 years, were mostly female (60%), and attained 15 years of education, on 
average. Not all participants completed the full protocol of cognitive tests due to either 
physical or cognitive handicap, refusal, or because tests were only introduced to the study 
protocol at a later time 
Procedures  
 Study procedures have been approved by the institutional review boards of the 
Nathan S. Kline Institute for Psychiatric Research and St. John’s University. A detailed 
account of operations of the MERI can be found in the MERI book chapter (Reichert et 
al., 2015).  Informed consent was obtained from all participants at initial contact. The 
components of the MERI that contributed to the current research include a detailed 
medical history, a brief medical exam, and a comprehensive neuropsychological battery. 
All medical data, including diagnoses of respiratory and cardiovascular disease and other 
medical history, as well as demographic information, were obtained by medical 
professionals via participant self-report during the intake process. Physiological 
measures, including blood-oxygen, blood pressure, and pulse, among other vital signs, 
were also measured at this time. Following intake, the neuropsychological test battery 
was administered by a trained psychometrician in a quiet room devoted to testing 
procedures. Following medical intake and neuropsychological testing, all MERI 
participants participated in a clinical interview with a geriatric psychiatrist.  
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 Data collected as part of the MERI were entered, stored, and cross-checked with 
paper files in a secure database. After all MERI visits, brief reports were compiled and 
reviewed in consultation with a clinical neuropsychologist and geriatric psychiatrist and 
results were mailed to participants.  
Neuropsychological Measures  
Descriptions of all neuropsychological tests administered as part of the MERI 
program are contained in the MERI book chapter (Reichert et al., 2015). Brief 
descriptions of the tests examined as part of the current study are provided below.  
Mini Mental State Examination (MMSE; Folstein et al., 1975).  Used as a 
measure of global cognitive functioning and a cutoff criterion (scores < 24) for cognitive 
impairment. The MMSE is a brief assessment that screens for potential problems in the 
areas of orientation, registration, attention and calculation, recall, and language. The test 
consists of both verbal and paper-and-pencil responses. The maximum score, indicating 
higher performance, is 30 points.  
Rey Auditory Verbal Learning Test (AVLT; Rey, 1958). Used as a measure of 
verbal memory, the AVLT encompasses five learning trials of a 15-word list, yielding a 
total recall score with a maximum of 75 words, an immediate test of uncued recall of 
words after an “interference” word list is presented, a delayed test of uncued recall of the 
original words after a 20-25 min delay, and a recognition task involving cued, multiple-
choice recall of the original word list. Scores represent the number of words accurately 
recalled.  
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Boston Naming Test (abridged; Kaplan et al., 1983). An abridged version of a 
60-item confrontation naming measure requires respondents to name what they see in 30 
drawings, which range from familiar objects to less familiar ones. If a participant fails to 
produce a response, a semantic cue is provided, followed by a phonetic cue if the 
respondent has difficulty naming even with a semantic cue. This test is used to assess 
language ability, with scores representing the number of items correctly named out of 30.  
Digit Symbol Substitution (Wechsler, 1939). A timed coding test in which 
participants are to use a key with paired numbers and symbols to complete a grid, which 
has numbers in the top portion and empty boxes in the lower portion, by filling in the 
corresponding symbols into the empty boxes. This test is used to measure both complex 
attention and processing speed, as well as serve as a proxy for executive functioning. 
Scores represent the number of symbols accurately transcribed. 
Grooved Pegboard (Lafayette Instruments; Model 32025). In this timed task, 
participants are asked to use metal pegs with one notched side to fill an arrangement of 
five rows with five slots each. Slots are oriented in different directions, requiring 
participants to maneuver pegs to fit accordingly. Scores on this test indicate the amount 
of time (in seconds) needed to complete the task. This test has separate trials for 
dominant and non-dominant hands. Grooved Pegboard is a more complex task of 
psychomotor functioning and is also a correlate of general cognitive ability. Because 
higher scores indicate poorer performance, scores were reversed for statistical analyses. 
Trail Making Test A (TMTA) & B (TMTB; Reitan, 1992). This test has two 
parts. Part A has participants draw lines sequentially connecting a series of circles with 
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numbers. Part A tests for attention and visual tracking, but also letter sequencing. The 
more complex Part B requires drawing lines sequentially, but this time alternating 
between both numbers and letters. Part B measures complex attention and the executive 
function of cognitive flexibility. Scores on this test indicate the amount of time (in 
seconds) needed to complete the task. Because higher scores indicate poorer 
performance, scores were reversed for statistical analyses.  
Verbal Fluency (FAS; Spreen & Benton, 1977) and Category Fluency 
(Animals; Moms et al., 1989). In Verbal Fluency (FAS), also known as the Controlled 
Oral Word Association Test (COWAT), participants are asked in three different trials to 
produce as many words as they can in 1 min that begin with the letters F, A, and S, 
respectively. Credit is not awarded for proper nouns, numbers, and the same word with a 
different suffix. In Category Fluency (Animals), participants are asked to name as many 
animals as they can in 1 min. These tests are associated with both executive functioning 
and the verbal fluency aspect of language. Scores on these tests indicate the amount of 
valid words produced in the allotted 1 min.  
Vocabulary. This test asks participants for definitions of words, ranging in 
difficulty level. It is an assessment of language attainment. Definitions are scored 
according to precision and quality, with higher scores indicating better performance.  
Although several of these tests may represent multiple cognitive domains, scores 
were aggregated to assess three core domains: global cognition, psychomotor 
functioning, and verbal ability. Categorization of domains was based largely on theory 
and precedents. Global cognition is an aggregate of scores for all neuropsychological 
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tests (excluding MMSE), representing a generalized level of overall cognitive 
performance in a more comprehensive manner than brief screeners like the MMSE that 
only contain one or several individual test items to represent domains. The 
psychomotor/executive functioning domain is an aggregate of scores of tests of higher-
order processing and psychomotor functioning (e.g., cognitive flexibility, processing 
speed, manual dexterity) and includes the following tests: Digit Symbol, Trail Making 
Test B, and Grooved Pegboard. Verbal ability is an aggregate of test scores that have a 
verbal or language component (e.g.., verbal memory and learning, verbal fluency, 
confrontation naming, letter sequencing) and includes the following tests: AVLT total 
recall, Verbal Fluency, Category Fluency, Trail Making Test A, Vocabulary, and Boston 
Naming. A visual depiction of domain aggregate scores can be found in Figure 1. 
Psychological Measures 
Depression. Multiple valid and reliable measures of depression were 
administered as part of the MERI program, including the Hamilton Depression Rating 
Scale (HAM-D; Hamilton, 1960), Beck Depression Inventory (BDI; Beck et al., 1996), 
Profile of Mood States (POMS; McNair et al., 1971), which has a Depression subscale, 
and the Geriatric Depression Scale (GDS; Yesavage et al., 1982). Aggregate scores of 
depression scales were used for participants who completed multiple scales.  
Anxiety. Scales of anxiety were also administered as part of the MERI, including 
the Hamilton Anxiety Rating Scale (HAM-A; Hamilton, 1959), Beck Anxiety Inventory 
(BAI; Beck et al., 1988), and Profile of Mood States (POMS; McNair et al., 1971), which 
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has a Tension-Anxiety subscale. Anxiety scale scores were also aggregated for 
participants who completed multiple scales. 
Medical Diseases 
Cardiovascular. Cardiovascular disease includes a wide range of heart-related 
conditions and illnesses. Some of the most common ones endorsed by participants 
include: hypertension, history of heart attack, atrial fibrillation, stents or pacemakers, 
arrythmia, coronary artery disease, and congestive heart failure. Cardiovascular disease 
was measured by patient self-report during intake. 
Respiratory. Respiratory disease in the current study includes self-reported 
history of the following: asthma, COPD, sleep apnea, and pulmonary fibrosis. 
Respiratory disease was measured by patient self-report during intake. 
Data Analytic Strategy 
Group differences among demographic variables were tested with either Chi-
square tests or independent samples t-tests. Zero-order correlations were used to assess 
for relationships between psychological, neuropsychological, and medical disease 
variables to identify variables of interest, test for multicollinearity, and justify 
aggregation of related scales. To test for relationships between independent variables and 
dependent variables, hierarchical multiple regressions were conducted for all three 
cognitive domains in three variations to allow for examination of groups that include all 
respiratory diseases, asthma alone, and COPD alone. On occasion, test scores presented 
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with extreme values. In these instances, winsorization was used to rectify the outlying 

















For possible differences between the respiratory and reference groups on 
demographic variables that relate to cognition, Chi-square tests and independent samples 
t-tests were conducted to evaluate group differences in gender, age, and years of formal 
education. The tests revealed no meaningful differences between the groups with respect 
to gender (p = .88), age (p = .23) and years of education (p = .42). Therefore, these 
demographic variables were omitted from further analyses. Additionally, aggregate 
anxiety scores did not demonstrate a meaningful relationship with either cardiovascular 
or respiratory disease and did not account for group differences (p > .05). It was, 
therefore, not implicated as a variable that suppressed the relationship between 
respiratory disease and cognition. As a result, anxiety was omitted from the primary 
analyses (i.e., regression analyses). Means and standard deviations for 
neuropsychological tests in raw score form and mean z-scores for aggregate depression 
and anxiety are provided in Table 1 for the whole sample, the respiratory disease group, 
and the cardiovascular disease group.  All aggregate scores (i.e., depression, anxiety, 
cognitive domains) were calculated by converting raw scores of individual tests to z-
scores, then adding scores together and taking the mean for each participant.  
Although anxiety did not correlate with either disease type, it did correlate 
meaningfully with depression (r = .83, p < .001) and weakly, but meaningfully, with the 
cognitive domains of global cognition (r = -.11, p < .001), psychomotor functioning (r = -
.13, p < .001), and verbal ability (r = -.09, p = .007), suggesting that higher levels of 
anxiety correspond to higher levels of depression and poorer performance in all cognitive 
 17 
domains. Additionally, all test scores correlated meaningfully with one another at the p < 
.001 level. This finding justifies the examination of a global cognition score that takes 
broader cognitive performance into account. This also served as a basis to create 
aggregate scores for the cognitive domains of psychomotor functioning and verbal 
ability. Similarly, all the depression subscales that comprise the aggregate depression 
score correlated with one another.   
Hierarchical regression analyses were performed in order to determine the impact 
of three groups of participants with respiratory disease (all, asthma, COPD) on global 
cognition, after controlling for the comorbidities of cardiovascular disease and 
depression. Preliminary analyses were conducted to ensure no violation of regression 
assumptions. Cardiovascular disease and depression were entered in the first step and 
respiratory disease group in the second step. As shown in Table 3, comorbidities (i.e., 
cardiovascular disease, depression) explained 4% of the variance in global cognition 
scores. Diagnosis of cardiovascular disease and higher depression scores were associated 
with poorer performance on overall cognition, β = -.07, p = .028 and β = -.18, p <.001, 
respectively. After entering respiratory disease at Step 2, the total variance explained by 
the model was 5%, F(3, 958) = 14.82, p < .001. Respiratory disease accounted for only 
an additional 1% of variance in the final model, β = .10, p = .002. Although small in 
effect, in the final model, all three variables, cardiovascular disease, depression, and 
respiratory disease, were statistically meaningful. Individual Beta values, standard errors, 
p-values, and change in R-squared can be found in Table 3. It is important to note that, 
contrary to hypothesis, those with respiratory disease were found to indicate better global 
cognitive performance.  
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To account for possible differences between groups of the most common 
respiratory diseases, asthma and COPD, hierarchical regressions were rerun two more 
times, entering asthma and COPD, respectively, into Step 2. Results can be found in 
Table 3. For both regression analyses, comorbidities (i.e., cardiovascular disease, 
depression) again explained 4% of the variance in global cognition scores. Diagnosis of 
cardiovascular disease and higher depression scores were associated with poorer 
performance on overall cognition. The first model revealed that cardiovascular disease 
and depression predicted global cognition scores for both asthma, F(2, 888) = 17.88, p < 
.001, and COPD, F(2, 868) = 18.90, p < .001, but after entering respiratory groups in 
Step 2, no additional variance was explained by the model and no meaningful effect was 
found for asthma (p = .131) or COPD (p = .106) on global cognition.  
Hierarchical regression analyses were also conducted to determine the relative 
impact of cardiovascular disease, depression, and respiratory group on psychomotor 
functioning.  As with earlier analyses, cardiovascular disease and depression were 
entered in the first step and respiratory disease group in the second step. As shown in 
Table 4, comorbidities (i.e., cardiovascular disease, depression) explained 5% of the 
variance in psychomotor functioning scores. Diagnosis of cardiovascular disease and 
higher depression scores were associated with poorer performance on psychomotor tasks, 
β = -.12, p < .001 and β = -.18, p < .001, respectively. This model revealed predictive 
power of these comorbidities on psychomotor functioning, F(2, 924) = 18.18, p < .001. 
Step 1 remained statistically meaningful in explaining variance in psychomotor 
functioning in regression analyses examining asthma (4%), F(2, 854) = 21.94, p < .001, 
and COPD (5%), F(2, 833) = 21.81, p < .001, independently. However, in all three 
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regressions, Step 2, that is, including respiratory group in the predictive model to explain 
psychomotor scores, did not explain additional variance in scores, suggesting no 
relationship between respiratory disease and psychomotor functioning when controlling 
for the effects of cardiovascular disease and depression.    
One final set of hierarchical regression analyses were performed in order to 
determine the impact of three groups of participants with respiratory disease (all, asthma, 
COPD) on verbal ability, after controlling for the comorbidities of cardiovascular disease 
and depression. Cardiovascular disease and depression were entered in the first step and 
respiratory disease group in the second step. As shown in Table 5, this model differed 
from regressions examining overall cognition and psychomotor ability in that 
comorbidities (i.e., cardiovascular disease, depression) only explained 2% of the variance 
in verbal ability scores and that even this effect was carried by depression, β = -.14, p < 
.001; F(2, 956) = 11.16, p < .001, and cardiovascular disease did not appear to share a 
meaningful relationship with verbal ability. After entering respiratory disease at step 2, 
the total variance explained by the model was 3%, F(3, 955) = 11.88, p < .001. All 
respiratory disease accounted for only an additional 1% of variance in the final model, β 
= .11, p < .001, revealing that respiratory disease diagnosis was related to higher verbal 
performance. In step 2, depression (p < .001) and respiratory disease (p < .001) 
meaningfully predicted verbal ability, whereas cardiovascular disease showed a possible 
trend (p = .059). As described, presence of comorbidities was related to poorer 
performance and presence of respiratory disease was related to better performance.  
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To further explore the unanticipated finding of respiratory disease predicting 
better verbal ability, hierarchical regressions were once again conducted two additional 
times, entering asthma and COPD, respectively, into Step 2. Results can be found in 
Table 5. For both regression analyses, comorbidities explained 3% of the variance in 
verbal ability, again carried primarily by depression, such that higher depression scores 
indicated poorer verbal ability in step 1 of regressions that examined asthma, F(2, 884) = 
11.53, p < .001, and COPD, F(2, 864) = 11.51, p < .001. However, in examining the 
additive predictive effect of COPD on verbal ability, it was found that, although the 
additional variance explained by this model was minimal (< 1%), COPD was 
meaningfully related to better verbal ability. Unlike with COPD, asthma offered no 
additional predictive effect on verbal ability.   
To explore further, additional multiple regressions were executed testing for 
moderation. All nine multiple regressions previously conducted (predicting scores on the 
three cognitive domains for three groups of respiratory disease) were re-run two more 
times, entering interaction terms for respiratory disease X cardiovascular disease and 
respiratory disease X depression, respectively into Step 3 of the regression analyses. 
Results of analyses revealed that interactions of the respiratory disease groups with 
cardiovascular disease and depression did not add any meaningful incremental prediction 
of cognitive scores for any of the domains (ps > .05).   
Means and standard deviations for physiological variables are reported in Table 6, 
along with clinical norms for an older adult population compiled from medical sources 
(Beasley et al., 2017; McCance & Huether, 2018; Whelton et al., 2018). With the 
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exception of systolic blood pressure, physiological measures (diastolic blood pressure, 
respiration, and oxygen saturation) were found to be in the normal range for all groups. 
Systolic blood pressure was found to be in the range consistent with Stage 2 
hypertension, not unexpected given that about 70% of the total sample reported 
diagnosed cardiovascular disease. Additionally, no meaningful differences between the 
respiratory and cardiovascular groups and their reference groups were found, except that 
those with self-reported cardiovascular disease had higher systolic blood pressure than a 
reference group without cardiovascular disease, t(957) = 1.84, p = .02, an expected and 
small effect.  Correlations were run to explore relationships between physiological 
measures and cognitive domains, also revealing no meaningful relationships between any 















The primary goals of the current study were to examine the relationship between a 
group of common respiratory diseases (asthma, COPD, sleep apnea, and pulmonary 
fibrosis) and global cognition, psychomotor functioning, and verbal ability in older 
adults, while also evaluating the impact of cardiovascular disease, depression, and 
anxiety in this relationship. It was hypothesized that cardiovascular disease and 
depression would both correlate with poorer cognitive functioning in all domains and 
that, after controlling for cardiovascular disease and depression, a relationship between 
respiratory disease and poorer functioning would emerge, with COPD demonstrating a 
stronger effect as compared to asthma.  
Regarding predictions about cardiovascular disease, the research largely 
supported the hypotheses. Cardiovascular disease was related to poorer performance on 
global cognition, which, when further broken down into the domains of psychomotor 
functioning and verbal ability, appeared to limit the effect to psychomotor functioning. 
Although a stronger effect was correctly predicted in the psychomotor domain, it was 
also expected that the effect would translate to verbal ability, which was not the case 
when verbal ability was examined apart from global cognition. As an aside, this may be 
consistent with the oft-cited distinction between crystallized and fluid intelligence, that 
crystallized intelligence can remain intact even in cognitively compromised populations, 
whereas fluid intelligence may decline sooner in compromised populations or in tandem 
with normal aging (Horn & Cattell, 1967). With regard to depression, hypotheses were 
fully supported. Depression predicted poorer functioning in global cognition, as well as 
when broken down into the domains of psychomotor and verbal ability. The effects of 
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cardiovascular disease and depression remained essentially unchanged across analyses of 
all included respiratory diseases, asthma alone, and COPD alone. Although the combined 
impact of cardiovascular disease and depression was meaningful, the effect was minimal. 
Only 2-3% of the variability in verbal ability scores and 4-5% in psychomotor scores was 
explained by cardiovascular disease and depression.  
Although when controlling for the noted effects of cardiovascular disease and 
depression, respiratory disease was found to meaningfully predict global cognition 
scores, it predicted better, not poorer, performance, contrary to hypothesis. This effect 
was also small, explaining only an additional 1% of variability in scores. Additionally, 
when examining this effect comparing asthma and COPD separately, neither one 
produced a significant effect on its own. Only the all-inclusive respiratory group 
exhibited the counterintuitive result. Further investigation revealed that with respect to 
psychomotor functioning, respiratory disease offered no statistical predictive quality on 
top of cardiovascular disease and depression. However, respiratory disease did add 
predictive quality over the comorbidities in the domain of verbal ability, possibly 
accounting for the effect seen in global cognition (which is comprised of verbal ability 
and psychomotor domains together). Furthermore, when comparing asthma to COPD in 
prediction of verbal ability scores, asthma alone did not appear to have an effect, whereas 
the COPD group seemed to account for the minimal effect predicting better verbal ability.  
 In summary, the only truly notable impact of respiratory disease on cognition was 
in the domain of verbal ability and the effect was a beneficial one, and more likely to be 
associated with COPD than asthma. This effect is counterintuitive, not only because the 
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direction of the relationship runs counter to previous research (e.g., Caldera-Alvarado et 
al., 2013; Dodd, 2015; Moss et al., 2005; Salık et al., 2007) and theoretical expectations, 
but especially because COPD, the more severe of the two types of respiratory disease, 
was the one that appears to account for the positive effect on verbal ability. Although it is 
possible to dismiss this finding because the statistical significance is borderline, the effect 
is minimal, and one could easily conclude that the current study is consistent with the 
research that respiratory disease in the elderly does not have a detectable impact on 
cognitive functioning, there may be a possible explanation for this effect. As noted 
earlier, some researchers have found that corticosteroid use can actually enhance some 
cognitive abilities, among them expressive language (Bozek et al., 2010; Prado & Crowe, 
2019). Due to the severe nature of COPD relative to asthma, corticosteroid use may be 
more frequent and perhaps this could explain the presence of a beneficial effect only for 
the COPD group and only for verbal ability in contrast to psychomotor functioning. 
Nonetheless, this is speculative as no data for medications or disease management were 
included in this study. Whatever the reason, these findings seem to indicate contrary to 
the approach of Yáñez et al. (2014) that COPD and asthma are essentially the same 
disease in the elderly, as differences were observed in the current research when 
contrasting asthma and COPD subgroups. It could be suggested that the disease types are 
similar with respect to their pathophysiology, but their clinical presentations and severity 
appear to remain different.  
 Regarding secondary aims/hypotheses, as expected, both anxiety and depression 
were associated with poorer cognition, globally and within both the psychomotor and 
verbal domains. Additionally, all individual cognitive tests that compromised the 
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domains correlated with another, as expected, allowing for creation of the aggregate 
domain scores, but also affirming data integrity in the process.  
 An additional aim of this research was to explore the relationship between 
physiological measures known to correlate with heart and respiratory disease and to 
examine their impact on cognition. A study of the whole sample, as well as isolating the 
cardiovascular and respiratory groups, revealed that on average, physiological measures 
were in the normal range for diastolic blood pressure, oxygen saturation, and respiration 
(breaths per minute). The exception, systolic blood pressure, was found to have a mean 
on the cusp of hypertensive disease, which is consistent with a sample whose majority 
has been diagnosed with cardiovascular disease/hypertension. Nonetheless, none of these 
measures appeared to relate to the cognitive domains in a meaningful way. Also, aside 
from those with cardiovascular disease showing higher systolic blood pressure than a 
reference group without it, no other differences on these measures were found between 
those with and without cardiovascular disease and with and without respiratory disease. It 
is likely to infer from this that, although these groups of people had self-reported 
diagnoses of disease, diseases were either well-controlled by medical treatment or the 
severity of disease was mild, thus reflecting generally normal levels of physical disease 
indicators. This may also lend understanding as to why, by and large, meaningful 
relationships did not emerge between respiratory disease and neuropsychological 
functioning and why the effect size was smaller than anticipated, even for the 
associations between cardiovascular disease and depression on cognition. Perhaps more 
meaningful associations may have been observed in a sample of patients with greater 
disease severity.  
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 Another point to consider regarding the failure to identify the expected negative 
relationship between respiratory disease and cognitive performance is that some have 
observed that asthma is underdiagnosed in the elderly (Banerjee et al., 1987; Stupka & 
deShazo, 2009). If this position is considered, it is possible the reference group utilized as 
a control for respiratory disease, a group of participants that was assumed to be cleared 
from diagnoses of respiratory diseases, may have, in fact, included those with undetected 
asthma, thereby skewing the results.    
Limitations, Challenges, and Future Directions 
Aside from those already alluded to, a number of limitations exist that may have 
impacted the extent of the findings or prevent generalization to clinical settings. Firstly, 
and perhaps most importantly, data on disease severity and treatment regimens were not 
obtained as part of this research. Data on reported severity may have been informative 
with respect to interpreting results and would have likely provided more context for the 
physiological data obtained. Additionally, accounting for the effects of medications, such 
as corticosteroids, may have provided more insight into results, as well. Another 
limitation may be the bias resulting from the “presenting problems” of the participants. 
As noted, MERI participants presented for neuropsychological testing primarily due to 
subjective memory or other cognitive complaints or out of concern due to aging and a 
family history of dementia or Alzheimer’s disease. Although medical history was 
examined peripherally, the focus of the parent research was not to validate the diagnoses 
of respiratory or cardiovascular disease nor to recruit from medically unstable 
populations. As mentioned, it is possible that recruitment of participants from pulmonary 
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or cardiovascular specialty clinics may have been more appropriate for this type of 
research.  
Another methodological downside using the MERI data for the current project is 
that neuropsychological test selection was intended to be sensitive to more basic 
cognitive changes typically associated with dementia and Alzheimer’s disease. Perhaps 
the impact of respiratory disease on cognition via cerebral oxygen deprivation may be 
more subtle and require more sensitive tests or comprehensive tests of higher-order 
functioning (e.g., Delis-Kaplan Executive Function System [DKEFS; Delis et al., 2012]). 
This is compounded by the fact that in an older adult population, the effects of normal 
cognitive aging may also be at play. Additionally, a challenge in all neuropsychological 
assessment is that often, an individual test may correlate with or assess multiple domains, 
complicating the interpretation of findings. For example, the Category Fluency test in the 
current study is conventionally used as a measure of verbal ability but is also widely used 
as a measure of executive functioning, possibly confounding the results. A research 
program focused more narrowly on the effects of respiratory disease may take these 
considerations into account.  
Finally, the current study only evaluated data at a single timepoint. Comparison of 
baseline functioning with performance at future visits, along with physiological measures 
obtained on multiple occasions, may provide a clearer picture of the clinical implications 
of medical disease on cognition.  
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Clinical Implications and Applications 
 There are numerous clinical implications of the current study. The relatively little 
the scientific community knows about how respiratory disease impacts 
neuropsychological functioning, let alone, in conjunction with comorbid conditions also 
known to impact functioning, can now benefit from expanded knowledge. Although 
results may be limited by the factors outlined above, in the current investigation the 
following basic pattern emerges: 1) depression relates to poorer cognition, globally, and 
within the individual domains of verbal ability and psychomotor functioning 2) 
cardiovascular disease relates to poorer functioning most significantly in the domain of 
psychomotor functioning 3) respiratory disease does not appear to explain cognitive 
performance, with the possible exception of COPD relating to enhanced performance in 
verbal ability. These findings can prepare medical practitioners to anticipate, as well as 
appropriately screen for neuropsychological impairment in the related domains. 
Monitoring and screening could then inform treatment planning and development of 
compensatory cognitive strategies, when indicated. For example, a patient who presents 
to a medical professional and is diagnosed with COPD may also be screened for 
depression and cardiovascular disease. Depending on the results, practitioners may want 
to refer for additional screening for deficits in either verbal or psychomotor domains. A 
patient with heart disease may be educated to apply extra caution when engaging in 
potentially hazardous motor-related tasks or be guided to maximize on the likelihood of 
preserved verbal and language functions in personal or professional settings.  
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Recently, the global COVID-19 pandemic has resulted in many infected patients 
presenting with oxygen deprivation secondary to hypoxic conditions not unlike those 
seen in asthma or COPD (Rahman et al., 2021). It has yet to be seen how COVID-19 may 
relate to cognition, especially longitudinally, but future research utilizing the theoretical 







































Means and Standard Deviations of Neuropsychological Test Raw Scores and Z-scores 





n = 969 
Respiratory 
Disease 
n = 196 
Cardiovascular 
Disease 
n = 678 
Neuropsychological Tests M (SD) M (SD) M (SD) 
MMSE 26.60 (4.80) 27.44 (3.76) 26.57 (4.72) 
AVLT-Total Recall 36.16 (14.03) 38.40 (12.34) 35.34 (13.67) 
Verbal Fluency (FAS) 37.00 (16.79) 40.22 (17.23) 36.39 (17.26) 
Category Fluency 14.63 (6.84) 16.37 (7.07) 14.37 (6.95) 
Boston Naming 22.89 (6.50) 23.87 (5.92) 22.73 (6.45) 
Vocabulary 11.05 (3.00) 11.41 (2.78) 11.06 (3.00) 
Trail Making Test A 50.85 (30.04) 47.58 (26.34) 52.53 (31.12) 
Trail Making Test B 115.91 (65.44) 112.59 (63.89) 119.87 (67.20) 
Digit Symbol 38.72 (14.38) 39.08 (14.63) 37.42 (14.14) 
Grooved Pegboard (DH) 110.52 (44.17) 108.98 (38.93) 112.68 (43.52) 
Grooved Pegboard (non DH) 121.16 (47.88) 123.19 (44.99) 124.07 (47.26) 
Aggregate Z-scores    
Depression -.01 (.86) .14 (.91) .01 (.89) 
Anxiety -.02 (.84) .09 (.90) .00 (.85) 
Note. For the following tests, higher scores represent poorer performance (i.e., time, in 
seconds, to complete the task): Grooved Pegboard, TMTA, TMTB. For all other tests, 
higher scores indicate better performance. For depression and anxiety, higher z-scores 








Correlation Coefficients of Neuropsychological Test Scores  
Note. * p  .001; AVLT = Auditory Verbal Learning Test; VF = Verbal Fluency; TMT = 
















 1 2 3 4 5 6 7 8 9 10 
1.  AVLT-Total  1          
2.  VF (FAS) .56* 1         
3.  VF (Animals) .66*   .65* 1        
4.  Boston Naming .58*   .55* .70* 1       
5.  Vocabulary .52*   .60*   .59*  .65* 1      
6.  TMT-A .49*  .45*  .56*  .52* .39* 1     
7.  TMT-B .47* .46*   .52*  .45* .38* .67* 1    
8.  Digit Symbol .63*  .59*   .67*   .61* .49* .72* .66* 1   
9.  GP (DH) .40* .27*   .40* .37* .31* .48* .43* .50* 1  
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